| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
7,090 |
5,967 |
$1.25M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12,599 |
11,850 |
$910K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
14,448 |
13,838 |
$889K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
2,941 |
2,818 |
$888K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
8,085 |
7,451 |
$562K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,777 |
1,699 |
$146K |
| 87640 |
|
4,301 |
4,039 |
$113K |
| 87486 |
|
4,047 |
3,813 |
$108K |
| 87581 |
|
4,051 |
3,819 |
$108K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
652 |
615 |
$70K |
| 87481 |
|
619 |
581 |
$45K |
| 87631 |
|
433 |
416 |
$38K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,264 |
1,221 |
$35K |
| 87653 |
|
930 |
882 |
$24K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
7,366 |
6,864 |
$14K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
208 |
201 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
440 |
428 |
$6K |
| 99051 |
|
5,418 |
5,064 |
$5K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
82 |
82 |
$4K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
57 |
55 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
79 |
66 |
$3K |
| 87541 |
|
157 |
151 |
$3K |
| 81003 |
|
936 |
895 |
$2K |
| 99215 |
Prolong outpt/office vis |
12 |
12 |
$1K |
| 87511 |
|
36 |
36 |
$1K |
| 87500 |
|
27 |
26 |
$885.82 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
12 |
12 |
$601.01 |
| 71046 |
Radiologic examination, chest; 2 views |
35 |
32 |
$573.99 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
44 |
40 |
$366.24 |
| 87807 |
|
17 |
16 |
$76.63 |
| 99072 |
|
12,282 |
11,383 |
$5.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
31 |
30 |
$1.83 |
| 99000 |
|
77 |
74 |
$0.00 |